Abstract-In order to investigate the antinephritic effect of Y-1 9018, a thromboxane A synthetase inhibitor, on crescentic-type anti-glomerular basement membrane (anti-GBM) nephritis in rats, the present study was undertaken. Male Sprague Dawley rats were immunized with rabbit r-globulin in Freund's complete adjuvant following i.v. injection of anti-GBM serum. Y-19018 at a dose of 0.3 and 3.0 mg/kg was given orally to rats from the day after the injection of anti-GBM serum (day 1) to day 39. Y-19018, 3.0 mg/kg, significantly inhibited both urinary protein excretion (30.6%) on day 19 and plasma cholesterol (39.8%) on day 15. Moreover, light microscopy demonstrated that this drug at both doses remarkably prevented histological involvement of the glomeruli on day 40 in a dose-dependent manner. In the blood obtained from nephritic rats, platelet aggregation was increased. Y 19018 suppressed (48.7%) the hyperaggregability of platelets on day 40 at a high dose, although the suppression of platelet aggregation was not in a dose-dependent manner. It is concluded from these data that Y-19018 shows beneficial effects on crescentic-type anti-GBM nephritis and may exert its action partly through inhibi tion of glomerular TXA2.
Recent studies have indicated that platelet aggregability was promoted (1) and platelet aggregates were increased in the circulation in patients with various forms of glomerulo nephritis (2) . Additionally, anti-platelet drugs could diminish protein excretion into urine and improve the kidney function in such cases. It is well-known that platelets are aggregated by a very small amount of thromboxane A2 (TXA2) as compared with other stimulants.
Lianos et al. (3) demon strated that thromboxane B2 (TXB2), a stable metabolite of TXA2, remarkably increased in the glomeruli 2 hr after the injection of nephrotoxic serum into rats and that the increase was sustained for 14 days. They also reported that there was a positive relation ship between the amount of glomerular TXB2 and the extent of proteinuria in that experi mental model. Therefore, it is expected that the decrease of TXA2 in glomerulonephritis could lead to an inhibition of the progress of glomerulonephritis.
In the present studies, we have found that Y-19018, a TXA syn thetase inhibitor, could suppress the develop ment of crescentic-type anti-GBM nephritis in rats.
Materials and Methods
Animals:
Male Sprague-Dawley rats (Sizuoka Jikken Dobutsu Kyodo Kumiai) weighing 160-170 g were used in the experiments.
2. Drugs (4): Y-19018 (2,4,6,2'-tetra methyl-b'-(l -imidazolyl)-diphenyl hydroxy methan) (Yoshitomi Seiyaku) was used. Y 19018 was suspended in 0.5% gum arabic solution. Animals orally received the drug in a volume of 1 ml/100 g of body weight.
3. Experimental nephritis and drug treat ment: Thirty-five rats were intravenously injected with 0.56 ml/animal of anti-GBM serum which was produced in rabbits as reported (5) . On the next day, 24 hr urinary protein was determined; and 3 groups were formed, each consisting of 8 rats with the same level of average proteinuria. Then, the rats of each group were subcutaneously immunized with 6.5 mg of rabbit r-globulin in 0.25 ml of Freund's complete adjuvant into the hind foot pads to induce crescentic type anti-GBM nephritis. Two of the 3 groups were administered daily with 0. 4. General condition, body weight and urine volume: The general condition of the rats was observed, and body weight and urine volume were determined during the experiment.
5. Urine, blood and kidney: Twenty-four hr urine samples were obtained on days 0, 5, 9, 29 and 39 after the injection of anti GBM serum. The animals were loaded with 8 ml of tap water and placed in separate metabolic cages for 24 hr without feeding and water. Urine was then centrifuged at 3,000 rpm for 20 min at 4°C, and the super natant was used for urinalysis. Blood samples were obtained on days 7, 15, 25 and 36 after the injection of anti-GBM serum. From the tall vein of conscious rats, 0.6 ml of blood was drawn with a disposable microsyringe and put into a tube with indomethacin at 2 itg/ml of blood and EDTA•2Na-2H2O at 4.5 ,cmol. The blood sample was centrifuged at 3,000 rpm for 20 min at 4°C, and the supernatant was employed as the plasma sample. On day 40, each of the animals was anesthetized with sodium pentobarbital (30 mg/kg) after the last collection of urine samples, and blood was gently drawn with a disposable syringe in the ratio of 9 parts blood to 1 part of 3.18% trisodium citrate from the renal vein to determine platelet aggregability. Then, the kidneys were immediately isolated and used as histopathological preparations. 6. Determination of biochemical para meters in urine and plasma: The protein content in urine was determined by the method of Kingsbury et al. (6) and expressed as mg per 24 hr urine. N-acetyl-(3 glucosaminidase (NAG) activity in urine was determined in accordance with the method of Hasebe (7) using 4-nitrophenyl-N-acetyl ,3-glucosaminide (Sigma) as substrate and expressed as mU per 24 hr urine. One unit refers to the ability to produce 1 ,uM of p nitrophenol from substrate for 1 hr incubation in 1 I of urine. Urea nitrogen content in plasma was determined by the urease indophenol spectrophotometric assay (8) . Cholesterol content in the plasma was determined with a commercial assay kit (Determina TC-5, Kyouwa Medix Co., Ltd.) (9) . Both urea nitrogen and cholesterol were expressed as mg per 1 dl of plasma.
7. Determination of platelet aggregability in whole blood: Platelet aggregability was measured with a whole blood aggregometer C-560 (Crono-log Co.). On day 40, 500 al of blood was added to 495 Id of 0.9% saline in a small aggregometer cuvette. This cuvette was maintained at 37°C by a heated block and the contents were stirred with a "flea" magnet. An electrode was inserted into the sample.
Five /cg of collagen (Collagen reagent Horm, Hormon-Chehen) was then added to a sample in the cuvette, and measurements were taken for 5 min. Results were represented as the conductance (ohm) between the two electrodes 5 min after the addition of aggregating agents. 8. Determination of blood pressure: Sys tolic blood pressure was measured before and 6, 12, 24, 30 and 37 days after the injection of anti-GBM serum by tall ple thysmography (KN-209, Natsume). Before the measurement, animals were warmed at 60°C for 3 min in the preheating box.
9. Light microscopic studies: The kidney was stepwise dehydrated and fixed by immersing the tissue into low to high con centrations of alcohol. Thereafter, the tissue was embedded in paraffin and cut into 3 ,um thick sections. Numbers indicate the mean±S.D. obtained from 8 rats. I',"~ and '"'I show significant difference from the normal at P<0.05, P<0.01 and P<0.001. Numbers in parentheses indicate inhibitory percentage: C-T X 100 (C: Control , T: Test drug, N: Normal). C-N Control rats showed severe proteinuria as high as 250 mg/day on day 1 after the i.v. injection of anti-GBM serum. On day 5, proteinuria once diminished to 85.8 mg/day, and then the largest amount of proteinuria was observed on day 19. On the other hand, 3.0 mg/kg Y-19018 resulted in about 30% less proteinuria than that of the control rats on day 19, which was a significant difference. In 0.3 mg/kg Y-1 9018, the rats showed the same level of proteinuria as that of the control rats.
NAG activity (Fig. 1 ): In the control group, the NAG activity in the urine was transiently increased on day 5. Y-19018 failed to sup press the increase in the activity at both doses.
Plasma cholesterol (Fig. 2) : The content of plasma cholesterol in control rats rapidly increased after the injection of anti-GBM serum, reaching a peak of 247.4 mg/dl on day 15. The administration of Y-19018 at 3 mg/kg significantly decreased plasma cholesterol to about 60% of that of the control group by day 15, and at 0.3 mg/kg, the drug had the tendency to diminish it from day 25.
Plasma urea nitrogen (Fig. 2 ): The control rats had a higher level of plasma urea nitrogen than that of the normal rats from day 1 5 after the i.v. injection of anti-GBM serum, and they exhibited a value of 22.2 mg/dl on day 36. However, the rats treated with Y 19018 revealed significantly less content of urea nitrogen on days 25 and 36 at 0.3 mg/ kg and on day 36 at 3.0 mg/kg in comparison with those in the control group. The inhibitory percentages varied from 50 to 70%. 4. Effect of Y-19018 on platelet aggregability (Fig. 3) While platelet aggregability was 7.8±3.1 S2 in the normal group, the control rats showed 12.9±2.6 Q on day 40, which was about 1.5 fold that of the normal rats. The inhibitory percentage of 3.0 mg/kg Y-1 9018 was 60.8% (9.8±1.6 Q). 5. Effect of Y-19018 on blood pressure ( Crescentic-type anti-GBM nephritis was used in this experiment to evaluate the anti nephritic effect of Y-19018. This model of nephritis is induced by the injection of anti GBM serum and rabbit r-globulin, and it shows more proteinuria and more severe glomerular alteration than those in the original-type of anti-GBM nephritis (10) .
In the present study, hyperaggregability of platelets, was demonstrated in the blood obtained from the nephritic rats on day 40. It is considered that in the heterologous phase, immune complexes are formed on the GBM after the injection of anti-GBM antibody, and then they activate the platelet (11, 12) . Furthermore, the exfoliation of endothelial cytoplasma from GBM is induced in this phase of anti-GBM nephritis and the collagen that is one of components in GBM is exposed to the circulation (13). This exposed GBM also stimulates the platelets. Therefore, we do not consider that Y-19018 exerts its effect on glomerular alteration through only the in hibition of platelet aggregation.
Lianos and his colleagues (3) demon strated that TXB2 remarkably increased in the glomeruli 2 hr after the i.v. injection of rabbit nephrotoxic serum into rats, and then this increase was sustained for 14 days. In their experiments, glomerular TXA2 could reduce the glomerular filtration rate and renal plasma flow after the injection of nephrotoxic serum. Therefore, Y-19018 may inhibit synthesis of the glomerular TXA2, and it may improve the micro circulation in the glomerulus and then inhibits the develop ment of glomerulonephritis.
Additionally, reduced GFR and RPF were restored by an increase of PG12 and PGE2 (3) . It was demonstrated that PG12 and PGE2 dilate renal blood vessels (15) and prominently increase renal blood flow (16) . PG12 also more strongly suppressed platelet aggregation than other prostanoids (17) . Since Y-19018 increases prostanoids including PG12 and PGE2 by inhibiting TXA2 synthetase (4), it is likely that Y-19018 may exert its action through not only inhibition of the glomerular TXA2 but also by effects on PG 12 and PGE2.
As TXA2 synthetase inhibitor seems to be a very promising antinephritic medicine from these results, experiments to evaluate the antinephritic effect of other TXA2 synthetase inhibitor are underway.
